The primary aim of this study is to evaluate the effect of Exenatide on weight status (change
in body mass index) of children treated for craniopharyngioma that have developed
hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that
Exenatide given to hypothalamic obese children for 6 months will reduce their body mass index
significantly from baseline.